Is Amneal Pharmaceuticals (AMRX) a Suitable Pick for Value Investors?Zacks Investment Research • 01/28/22
Amneal's $83M Saol Acquisition Deal Expands Its Neurology Presence Into SpasticityBenzinga • 01/05/22
Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/21/21
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Amneal Posts Mixed Bag Q3 Earnings; Acquires Puniska To Bolster Injectable BusinessBenzinga • 11/03/21
Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible CompanyBusiness Wire • 11/02/21
Amneal Pharmaceuticals (AMRX) to Report Q3 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 10/29/21
Why the Earnings Surprise Streak Could Continue for Amneal (AMRX)Zacks Investment Research • 10/25/21
Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare ConferenceBusiness Wire • 09/07/21
Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson's Disease Who Experience Motor FluctuationsBusiness Wire • 08/25/21
Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson's Disease Who Experience Motor FluctuationsBusiness Wire • 08/23/21
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/09/21